The iconic rise of copyright’s flagship product presented a considerable chance for investors , but its period has expired , creating a intricate landscape. Generic versions have appeared in the market , eroding revenues and putting a squeeze on profit margins . While leading pharmaceutical companies hold a presence in this field , the future see